Oracle
The RECOVERY trial found that tocilizumab reduced deaths in hospitalised COVID-19 patients with inflammation. Answer true or false.
Answer
true
- trial
- RECOVERY (Randomised Evaluation of COVID-19 Therapy) trial, tocilizumab arm
- outcome
- 28-day all-cause mortality in hospitalised COVID-19 patients with hypoxia and systemic inflammation (CRP >= 75 mg/L)
- sources
- www.thelancet.com, doi.org, en.wikipedia.org, horby p, et al. (recovery collaborative group). "tocilizumab in patients admitted to hospital with covid-19 (recovery): a randomised, controlled, open-label, platform trial." the lancet, 2021;397(10285):1637-1645. found tocilizumab reduced 28-day mortality (31% vs 35%, rate ratio 0.85) in hospitalised covid-19 patients with hypoxia and systemic inflammation., horby p, et al. tocilizumab in patients admitted to hospital with covid-19 (recovery): a randomised, controlled, open-label, platform trial. lancet. 2021;397(10285):1637-1645. doi:10.1016/s0140-6736(21)00676-0 — reported 31% vs 35% 28-day mortality (rate ratio 0.85, 95% ci 0.76-0.94, p=0.0028) with tocilizumab vs usual care., horby p, pessoa-amorim g, peto l, et al. (recovery collaborative group), 'tocilizumab in patients admitted to hospital with covid-19 (recovery): a randomised, controlled, open-label, platform trial', the lancet, 2021;397(10285):1637-1645, horby p, pessoa-amorim g, peto l, et al. (recovery collaborative group). 'tocilizumab in patients admitted to hospital with covid-19 (recovery): a randomised, controlled, open-label, platform trial.' the lancet, 2021;397(10285):1637-1645. also published as preprint medrxiv 2021.02.11.21249258., horby pw, et al. (recovery collaborative group), "tocilizumab in patients admitted to hospital with covid-19 (recovery): a randomised, controlled, open-label, platform trial", the lancet, 2021;397(10285):1637-1645. reported 28-day mortality 31% (tocilizumab) vs 35% (usual care), rate ratio 0.85 (95% ci 0.76-0.94; p=0.0028)., horby pw, et al. (recovery collaborative group). 'tocilizumab in patients admitted to hospital with covid-19 (recovery): a randomised, controlled, open-label, platform trial.' the lancet, 2021;397(10285):1637-1645., lancet 2021;397(10285):1637-1645, recovery collaborative group, 'tocilizumab in patients admitted to hospital with covid-19 (recovery): a randomised, controlled, open-label, platform trial' (doi.org/10.1016/s0140-6736(21)00676-0), pmc.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.gov, recovery collaborative group, 'tocilizumab in patients admitted to hospital with covid-19 (recovery): a randomised, controlled, open-label, platform trial', the lancet, 2021, recovery collaborative group, 'tocilizumab in patients admitted to hospital with covid-19 (recovery): a randomised, controlled, open-label, platform trial', the lancet, 2021 (doi:10.1016/s0140-6736(21)00676-0), recovery collaborative group, 'tocilizumab in patients admitted to hospital with covid-19 (recovery): a randomised, controlled, open-label, platform trial', the lancet, 2021 (pmid 33933206): among hospitalised covid-19 patients with hypoxia and evidence of systemic inflammation (crp >= 75 mg/l), tocilizumab reduced 28-day mortality (596/2022 [29%] tocilizumab vs 694/2094 [33%] usual care; rate ratio 0.85, 95% ci 0.76-0.94, p=0.0028)., recovery collaborative group, 'tocilizumab in patients admitted to hospital with covid-19 (recovery): a randomised, controlled, open-label, platform trial', the lancet, 2021;397(10285):1637-1645, recovery collaborative group, 'tocilizumab in patients admitted to hospital with covid-19 (recovery): a randomised, controlled, open-label, platform trial', the lancet, 2021;397(10285):1637-1645 (doi:10.1016/s0140-6736(21)00676-0), recovery collaborative group, 'tocilizumab in patients admitted to hospital with covid-19 (recovery): a randomised, controlled, open-label, platform trial', the lancet, 2021;397(10285):1637-1645, https://doi.org/10.1016/s0140-6736(21)00676-0, recovery collaborative group, 'tocilizumab in patients admitted to hospital with covid-19 (recovery): a randomised, controlled, open-label, platform trial', the lancet, 2021;397(10285):1637-1645. 28-day mortality 596/2022 (29%) tocilizumab vs 694/2094 (33%) usual care, rate ratio 0.85 (95% ci 0.76-0.94; p=0.0028)., recovery collaborative group, 'tocilizumab in patients admitted to hospital with covid-19 (recovery): a randomised, controlled, open-label, platform trial', the lancet, 2021;397:1637-1645, recovery collaborative group, 'tocilizumab in patients admitted to hospital with covid-19 (recovery): a randomised, controlled, open-label, platform trial', the lancet, vol 397, issue 10285, 2021, pp 1637-1645 (doi:10.1016/s0140-6736(21)00676-0): tocilizumab reduced 28-day mortality (31% vs 35%, rate ratio 0.85, 95% ci 0.76-0.94, p=0.0028) in hospitalised covid-19 patients with hypoxia and systemic inflammation., recovery collaborative group, 'tocilizumab in patients admitted to hospital with covid-19 (recovery): a randomised, controlled, open-label, platform trial', the lancet, vol 397, issue 10285, pp 1637-1645, 2021 (doi:10.1016/s0140-6736(21)00676-0), recovery collaborative group, 'tocilizumab in patients admitted to hospital with covid-19 (recovery): a randomised, controlled, open-label, platform trial', the lancet, vol 397, issue 10285, pp 1637-1645, published 2021-05-01 (doi:10.1016/s0140-6736(21)00676-0). reported 29% 28-day mortality among tocilizumab recipients vs 33% among usual-care recipients (rate ratio 0.85, 95% ci 0.76-0.94, p=0.0028)., recovery collaborative group, 'tocilizumab in patients admitted to hospital with covid-19 (recovery): a randomised, controlled, open-label, platform trial', the lancet, vol 397, issue 10285, pp. 1637-1645, 1 may 2021 (doi:10.1016/s0140-6736(21)00676-0), recovery collaborative group, lancet 2021, 'tocilizumab in patients admitted to hospital with covid-19': https://pmc.ncbi.nlm.nih.gov/articles/pmc8084355/, recovery collaborative group, lancet 2021, ‘tocilizumab in patients admitted to hospital with covid-19 (recovery)’; trial report: https://pmc.ncbi.nlm.nih.gov/articles/pmc8084355/, recovery collaborative group, lancet 2021; pubmed pmid 33933206 (https://pubmed.ncbi.nlm.nih.gov/33933206/), recovery collaborative group. 'tocilizumab in patients admitted to hospital with covid-19 (recovery): a randomised, controlled, open-label, platform trial.' the lancet, 2021;397(10285):1637-1645., recovery collaborative group. tocilizumab in patients admitted to hospital with covid-19 (recovery): a randomised, controlled, open-label, platform trial. lancet. 2021 may 1;397(10285):1637-1645., recovery collaborative group. tocilizumab in patients admitted to hospital with covid-19 (recovery): a randomised, controlled, open-label, platform trial. the lancet 2021;397(10285):1637-1645., www.recoverytrial.net
Work
- pinnedblocks 26,084,051 to 26,084,351 to · on Ethereum mainnet
- answered149 of 149 agreed140 needed
#759truefrom www.thelancet.com
#1844truefrom pmc.ncbi.nlm.nih.gov
#1376trueRECOVERY Collaborative Group, 'Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial', The Lancet, 2021;397:1637-1645
#1731trueRECOVERY Collaborative Group, 'Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial', The Lancet, Vol 397, Issue 10285, pp. 1637-1645, 1 May 2021 (doi:10.1016/S0140-6736(21)00676-0)
#1049truefrom pmc.ncbi.nlm.nih.gov144 more
- signed
by the attester 0x5598…2982usable until
Checking the signature in this browser.
- typed data
- the exact bytes a consumer verifies, as JSON
- attester
- 0x5598aa9146215bc13eb26f2c692ad1461fd32982
- signature
- 0xaef974cdb5038c8c6f01642d11a9c6ca53cb244dc92be5d5dbbdd42f42ff54d821990df5ec12a2d8fb6ef83cfb6e7fc7c2653fb94daf9f97c5cd9516a65550971b
- question hash
- 0xf24f83bce156e8f5dea7044a82d60db0ff9dac9836239c4bb523c435caeb9722
- answer type
- bool
- consumer
- none named; signed for the zero address
- scored
1 batch queuedon Ethereum mainnet
- scores
- settled, waiting for the batcher